Lorenzini Stefania, Gitto Stefano, Grandini Elena, Andreone Pietro, Bernardi Mauro
Dipartimento di Medicina Clinica, Via Massarenti 9, Bologna, Italy.
World J Gastroenterol. 2008 Aug 7;14(29):4593-9. doi: 10.3748/wjg.14.4593.
End stage liver disease (ESLD) is a health problem worldwide. Liver transplantation is currently the only effective therapy, but its many drawbacks include a shortage of donors, operative damage, risk of rejection and in some cases recidivism of the pre-transplant disease. These factors account for the recent growing interest in regenerative medicine. Experiments have sought to identify an optimal source of stem cells, sufficient to generate large amounts of hepatocytes to be used in bioartificial livers or injected in vivo to repair the diseased organ. This update aims to give non-stem cell specialists an overview of the results obtained to date in this fascinating field of biomedical research.
终末期肝病（ESLD）是一个全球性的健康问题。肝移植是目前唯一有效的治疗方法，但其诸多缺点包括供体短缺、手术损伤、排斥风险以及在某些情况下移植前疾病的复发。这些因素导致近期对再生医学的兴趣日益浓厚。实验一直在寻找最佳的干细胞来源，以产生大量肝细胞用于生物人工肝或注入体内修复患病器官。本综述旨在让非干细胞专家了解这一引人入胜的生物医学研究领域迄今为止所取得的成果。
